Trials / Completed
CompletedNCT05962151
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Trevi Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effect of NAL ER on 24-hour cough frequency and to assess safety and tolerability of NAL-ER for treatment of refractory chronic cough.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NAL ER | Oral tablets |
| DRUG | Placebo | Oral tablets |
Timeline
- Start date
- 2023-11-30
- Primary completion
- 2025-01-06
- Completion
- 2025-01-06
- First posted
- 2023-07-27
- Last updated
- 2026-03-30
- Results posted
- 2026-03-30
Locations
14 sites across 2 countries: Canada, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05962151. Inclusion in this directory is not an endorsement.